临床试验用品市场－全球产业规模、份额、趋势、机会及预测（依临床阶段、产品/服务、治疗用途、最终用户、地区及竞争格局划分，2021-2031年）

全球临床试验用品市场预计将从 2025 年的 31.8 亿美元成长到 2031 年的 49.8 亿美元，复合年增长率为 7.76%。

此业务板块涵盖范围广泛，包括临床实验药物、医疗设备以及检测套组、包装材料等辅助用品，这些都是合规研究不可或缺的环节。成长的主要驱动力来自全球临床试验数量的增加以及生物製药行业研发投入的不断增长。此外，对生物製药和孤儿药日益增长的关注也需要专业的处理和物流，从而推动了对安全可靠的供应链解决方案的需求。

然而，市场面临着与复杂低温运输管理相关的重大障碍，尤其是对温度敏感的生物製药，这些製品在运输过程中需要严格的环境控制。不同地区的法规差异也带来了合规的挑战，可能导致供应延迟和营运成本增加。欧洲製药工业协会联合会（EFPIA）的报告显示，到2024年，“欧洲以研发为基础的製药行业预计将在研发方面投入550亿欧元”，这表明构建这一基础设施所需的投资规模巨大，也凸显了建立高效供应链以维持如此巨额投资的必要性。

市场驱动因素

不断上涨的医药和生物製药研发成本是推动全球临床试验供应市场发展的主要因素。随着企业寻求治疗慢性病和罕见疾病的新治疗方法，财务支出必然需要增加临床实验药物及相关耗材的购买。这种投资的增加推动了对精准供应链物流的需求，以管理全球各地设施的物资配送。例如，罗氏公司于2025年1月发布的《2024年财务报告》预测，该公司研发成本将达到130亿瑞士法郎，显示在治疗方法开发上投入庞大。这需要大量的临床供应支援。

同时，全球註册的临床试验数量不断增加，显着扩大了供应商的业务范围，也推动了市场成长。这种成长，尤其是对于复杂的生物製药而言，需要强大的基础设施来确保产品品质和在不同地区的及时企业发展。根据美国国立卫生研究院 (NIH) 于 2025 年 4 月发表的题为《ClinicalTrials.gov：25 年註册 50 万项研究的征程》的报导，该註册系统将于 2024 年註册其第 50 万项临床研究，凸显了需要供应链管理的庞大研究规模。为了因应这一日益增长的需求，Cencora 在 2025 年 11 月发布的新闻稿《Cencora 宣布投资 10 亿美元》中宣布，计划在 2030 年投资 10 亿美元，以加强其药品分销网络。

市场挑战

低温运输管理的复杂性对全球临床试验供应市场的发展构成重大障碍。随着产业向生物製药和孤儿药领域转型，严格的环境控制要求使得物流结构变得特别复杂。这些对温度敏感的产品从生产到给药都需要持续冷藏或冷冻。运输过程中的温度波动会导致临床实验药物失效，造成重大经济损失并延误试验。这种脆弱性迫使企业投入高昂成本用于专用包装和监控系统，从而加剧预算压力，并限制了基础设施欠发达地区市场的有效扩张。

目前正在研发的敏感治疗药物数量庞大，进一步加剧了物流压力。根据美国药品研究与製造商协会（PhRMA）预测，到2024年，全球将有超过8,000种药物处于临床研发阶段，其中大部分是需要严格温度控制的生物製药。如此庞大数量的温控产品运输管理难度增加，导致废弃物风险上升。在复杂的环境下，供应链中断的可能性增加，限制了临床试验向新地区的拓展，并抑制了整个供应市场的成长潜力。

市场趋势

临床试验（DCT）供应物流向分散式模式的转变正在重塑市场格局，将治疗点从标准研究机构转移到患者家中。这种模式需要灵活的供应链，以便在严格控制温度和监管链的前提下，将药品直接送达患者手中。为了支援这种分散式模式，物流供应商正在建造超区域配销中心，以确保即使在传统临床环境之外也能遵守通讯协定。 2025年4月发布的新闻稿「DHL集团计画在2030年向DHL健康物流投资20亿欧元」便是这项转变的有力佐证。 DHL集团在新闻稿中宣布，将投资20亿欧元以加强其生命科学物流业务，尤其旨在满足复杂试验设计中对专业服务的需求。

同时，人工智慧 (AI) 与需求预测的整合正在推动预测性库存管理的发展。透过分析患者入组率和使用模式等数据，AI 演算法能够准确预测供应需求，从而最大限度地减少药物浪费并防止短缺。这项功能使申办方能够即时调整其交付策略，确保在需要时获得充足的供应。例如，赛默飞世尔科技在 2025 年 10 月的新闻稿《赛默飞世尔科技携手 OpenAI 加速生命科学领域的突破》中指出，该公司正在其 PPD 临床研究部门部署人工智慧，以「缩短」临床试验週期并加快药物研发。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球临床试验用品市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依临床阶段（I期、II期、III期、其他）
  • 依产品/服务（製造、仓储/配送、供应链管理）分类
  • 依治疗用途（肿瘤、中枢神经系统疾病、心血管疾病、感染疾病、代谢性疾病、其他）
  • 按最终使用者（药品、生物药品、医疗设备、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美临床试验用品市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲临床试验用品市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太临床试验用品市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲临床试验用品市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲临床试验用品市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球临床试验用品市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc.
• Almac Group
• Novo Holdings A/S
• Marken LLP
• PCI Pharma Services
• Sharp Services LLC
• Cencora, Inc.
• Myonex LLC
• Parexel International Corporation
• ICON Plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Clinical Trial Supplies Market is projected to expand from USD 3.18 Billion in 2025 to USD 4.98 Billion by 2031, registering a CAGR of 7.76%. This sector encompasses a wide array of necessities, including investigational medicinal products, medical devices, and ancillary items like testing kits and packaging essential for compliant studies. Growth is largely fueled by the escalating number of clinical trials globally and rising research and development investments within the biopharmaceutical industry. Furthermore, the increasing emphasis on biologics and orphan drugs requires specialized handling and logistics, thereby boosting the demand for secure and resilient supply chain solutions.

However, the market encounters substantial obstacles related to complex cold chain management, especially for temperature-sensitive biologics that require rigorous environmental controls during transit. Varying regulations across different regions also introduce compliance difficulties that can delay supply schedules and raise operational expenses. Highlighting the scale of investment requiring this infrastructure, the 'European Federation of Pharmaceutical Industries and Associations' reported in '2024' that 'the research-based pharmaceutical industry invested an estimated 55,000 million euros in research and development in Europe', confirming the vital need for efficient supply chain mechanisms to sustain such significant financial commitments.

Market Driver

Rising pharmaceutical and biopharmaceutical R&D spending acts as a major engine for the Global Clinical Trial Supplies Market. As companies strive to discover new treatments for chronic and rare conditions, their financial outlays necessitate a corresponding increase in acquiring investigational products and ancillary supplies. This heightened investment drives the demand for precise supply chain logistics to handle material distribution across global sites. For instance, according to Roche, January 2025, in the 'Finance Report 2024', the company's research and development expenditure hit 'CHF 13.0 billion', illustrating the massive capital directed toward therapeutic advancement that requires extensive clinical supply backing.

Concurrently, the market is propelled by the growing volume of registered clinical trials worldwide, which significantly broadens the operational landscape for vendors. This increase, especially with complex biologics, calls for strong infrastructure to guarantee product quality and timely delivery across varied locations. According to the National Institutes of Health, April 2025, in the article 'ClinicalTrials.gov: A 25-Year Journey to a Half-Million Registered Studies', the registry recorded its '500,000th' clinical study in 2024, emphasizing the vast scale of research needing supply management. To meet these rising needs, according to Cencora, November 2025, in the 'Cencora Announces $1 Billion Investment' press release, the firm intends to invest '$1 billion' through 2030 to strengthen its pharmaceutical distribution network.

Market Challenge

The intricacies of cold chain management present a significant hurdle to the advancement of the global clinical trial supplies market. With the industry pivoting toward biologics and orphan drugs, the necessity for stringent environmental controls results in a delicate logistical framework. These temperature-sensitive items require continuous refrigeration or freezing from production through to administration; any temperature deviation during transport can spoil investigational products, causing major financial setbacks and study delays. This susceptibility compels companies to incur high expenses for specialized packaging and monitoring, straining budgets and limiting efficient market scalability in regions with developing infrastructure.

This logistical pressure is further amplified by the sheer volume of sensitive therapies currently in the pipeline. According to the 'Pharmaceutical Research and Manufacturers of America', in '2024', 'there were more than 8,000 medicines in clinical development' worldwide, a large portion of which are biologics requiring strict temperature maintenance. Managing the shipment of such a vast quantity of sensitive products heightens the risk of waste. Consequently, the elevated likelihood of supply chain failures in complex environments restricts the reach of clinical trials into new regions, thereby curbing the overall growth potential of the supplies market.

Market Trends

The move toward Decentralized Clinical Trial (DCT) supply logistics is reshaping the market by shifting care from standard investigator sites to patients' homes. This approach requires flexible supply chains that can handle direct-to-patient deliveries while strictly upholding temperature controls and chain of custody. To support this dispersed model, logistics providers are creating hyper-local distribution centers that ensure protocol compliance outside of traditional clinical environments. Confirming this shift, according to DHL Group, April 2025, in the 'DHL Group to Invest EUR 2 Billion by 2030 in DHL Health Logistics' press release, the firm has pledged '€2 billion' to bolster its life sciences logistics, specifically aiming to meet demand for specialized services in complex trial designs.

At the same time, the integration of Artificial Intelligence for Demand Forecasting is refining inventory management via predictive analytics. By analyzing data such as enrollment speeds and usage patterns, AI algorithms can accurately anticipate supply requirements, thereby minimizing drug waste and preventing shortages. This capability enables sponsors to adapt distribution strategies in real-time, ensuring materials are on hand exactly when required. Illustrating this development, according to Thermo Fisher Scientific, October 2025, in the 'Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI' press release, the company has incorporated artificial intelligence throughout its PPD clinical research division to 'improve the cycle time' of trials and speed up drug development.

Key Market Players

• Thermo Fisher Scientific Inc.
• Almac Group
• Novo Holdings A/S
• Marken LLP
• PCI Pharma Services
• Sharp Services LLC
• Cencora, Inc.
• Myonex LLC
• Parexel International Corporation
• ICON Plc

Report Scope

In this report, the Global Clinical Trial Supplies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Trial Supplies Market, By Clinical Phase

• Phase I
• Phase II
• Phase III
• Others

Clinical Trial Supplies Market, By Product & Services

• Manufacturing
• Storage & Distribution
• Supply Chain Management

Clinical Trial Supplies Market, By Therapeutic Use

• Oncology
• CNS Diseases
• Cardiovascular Diseases
• Infectious Disease
• Metabolic Disorders
• Others

Clinical Trial Supplies Market, By End User

• Pharmaceutical
• Biologics
• Medical device
• Others

Clinical Trial Supplies Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Trial Supplies Market.

Available Customizations:

Global Clinical Trial Supplies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clinical Trial Supplies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Clinical Phase (Phase I, Phase II, Phase III, Others)
  • 5.2.2. By Product & Services (Manufacturing, Storage & Distribution, Supply Chain Management)
  • 5.2.3. By Therapeutic Use (Oncology, CNS Diseases, Cardiovascular Diseases, Infectious Disease, Metabolic Disorders, Others)
  • 5.2.4. By End User (Pharmaceutical, Biologics, Medical device, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Clinical Trial Supplies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Clinical Phase
  • 6.2.2. By Product & Services
  • 6.2.3. By Therapeutic Use
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Clinical Trial Supplies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Clinical Phase
      • 6.3.1.2.2. By Product & Services
      • 6.3.1.2.3. By Therapeutic Use
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Clinical Trial Supplies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Clinical Phase
      • 6.3.2.2.2. By Product & Services
      • 6.3.2.2.3. By Therapeutic Use
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Clinical Trial Supplies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Clinical Phase
      • 6.3.3.2.2. By Product & Services
      • 6.3.3.2.3. By Therapeutic Use
      • 6.3.3.2.4. By End User

7. Europe Clinical Trial Supplies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Clinical Phase
  • 7.2.2. By Product & Services
  • 7.2.3. By Therapeutic Use
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Clinical Trial Supplies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Clinical Phase
      • 7.3.1.2.2. By Product & Services
      • 7.3.1.2.3. By Therapeutic Use
      • 7.3.1.2.4. By End User
  • 7.3.2. France Clinical Trial Supplies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Clinical Phase
      • 7.3.2.2.2. By Product & Services
      • 7.3.2.2.3. By Therapeutic Use
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Clinical Trial Supplies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Clinical Phase
      • 7.3.3.2.2. By Product & Services
      • 7.3.3.2.3. By Therapeutic Use
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Clinical Trial Supplies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Clinical Phase
      • 7.3.4.2.2. By Product & Services
      • 7.3.4.2.3. By Therapeutic Use
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Clinical Trial Supplies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Clinical Phase
      • 7.3.5.2.2. By Product & Services
      • 7.3.5.2.3. By Therapeutic Use
      • 7.3.5.2.4. By End User

8. Asia Pacific Clinical Trial Supplies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Clinical Phase
  • 8.2.2. By Product & Services
  • 8.2.3. By Therapeutic Use
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Clinical Trial Supplies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Clinical Phase
      • 8.3.1.2.2. By Product & Services
      • 8.3.1.2.3. By Therapeutic Use
      • 8.3.1.2.4. By End User
  • 8.3.2. India Clinical Trial Supplies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Clinical Phase
      • 8.3.2.2.2. By Product & Services
      • 8.3.2.2.3. By Therapeutic Use
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Clinical Trial Supplies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Clinical Phase
      • 8.3.3.2.2. By Product & Services
      • 8.3.3.2.3. By Therapeutic Use
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Clinical Trial Supplies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Clinical Phase
      • 8.3.4.2.2. By Product & Services
      • 8.3.4.2.3. By Therapeutic Use
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Clinical Trial Supplies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Clinical Phase
      • 8.3.5.2.2. By Product & Services
      • 8.3.5.2.3. By Therapeutic Use
      • 8.3.5.2.4. By End User

9. Middle East & Africa Clinical Trial Supplies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Clinical Phase
  • 9.2.2. By Product & Services
  • 9.2.3. By Therapeutic Use
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Clinical Trial Supplies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Clinical Phase
      • 9.3.1.2.2. By Product & Services
      • 9.3.1.2.3. By Therapeutic Use
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Clinical Trial Supplies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Clinical Phase
      • 9.3.2.2.2. By Product & Services
      • 9.3.2.2.3. By Therapeutic Use
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Clinical Trial Supplies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Clinical Phase
      • 9.3.3.2.2. By Product & Services
      • 9.3.3.2.3. By Therapeutic Use
      • 9.3.3.2.4. By End User

10. South America Clinical Trial Supplies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Clinical Phase
  • 10.2.2. By Product & Services
  • 10.2.3. By Therapeutic Use
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Clinical Trial Supplies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Clinical Phase
      • 10.3.1.2.2. By Product & Services
      • 10.3.1.2.3. By Therapeutic Use
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Clinical Trial Supplies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Clinical Phase
      • 10.3.2.2.2. By Product & Services
      • 10.3.2.2.3. By Therapeutic Use
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Clinical Trial Supplies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Clinical Phase
      • 10.3.3.2.2. By Product & Services
      • 10.3.3.2.3. By Therapeutic Use
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Clinical Trial Supplies Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Almac Group
• 15.3. Novo Holdings A/S
• 15.4. Marken LLP
• 15.5. PCI Pharma Services
• 15.6. Sharp Services LLC
• 15.7. Cencora, Inc.
• 15.8. Myonex LLC
• 15.9. Parexel International Corporation
• 15.10. ICON Plc

16. Strategic Recommendations

17. About Us & Disclaimer